Oncolytics Biotech is a company developing Pelareorep, an intravenously delivered immuno-oncolytic virus, used for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic isolate of the unmodified reovirus that induces selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses.